Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Common Equity (2022 - 2025)

Zentalis Pharmaceuticals has reported Common Equity over the past 4 years, most recently at $216.2 million for Q4 2025.

  • Quarterly results put Common Equity at $216.2 million for Q4 2025, down 35.88% from a year ago — trailing twelve months through Dec 2025 was $216.2 million (down 35.88% YoY), and the annual figure for FY2025 was $216.2 million, down 35.88%.
  • Common Equity for Q4 2025 was $216.2 million at Zentalis Pharmaceuticals, down from $252.9 million in the prior quarter.
  • Over the last five years, Common Equity for ZNTL hit a ceiling of $523.3 million in Q2 2023 and a floor of $216.2 million in Q4 2025.
  • Median Common Equity over the past 4 years was $384.1 million (2023), compared with a mean of $378.2 million.
  • Biggest five-year swings in Common Equity: grew 22.18% in 2023 and later plummeted 35.88% in 2025.
  • Zentalis Pharmaceuticals' Common Equity stood at $434.0 million in 2022, then increased by 0.75% to $437.3 million in 2023, then fell by 22.89% to $337.2 million in 2024, then plummeted by 35.88% to $216.2 million in 2025.
  • The last three reported values for Common Equity were $216.2 million (Q4 2025), $252.9 million (Q3 2025), and $274.5 million (Q2 2025) per Business Quant data.